Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
CorMedix Inc.'s quarterly P/E stands at 19.4x, up 110.6% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has compressed 55.4% YoY to 3.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 3.88 | 19.38 | 2.31 | 11.00 | 5.13 | 9.20 | — | — | — | — | — | — | 0.11 |
| — | +110.6% | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.99 | 2.12 | 2.40 | 5.57 | 2.72 | 3.99 | 10.37 | 77.38 | — | — | — | — | — |
| — | -46.8% | -76.8% | -92.8% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.57 | 2.69 | 2.68 | 4.02 | 3.70 | 5.89 | 8.10 | 5.40 | 4.20 | 3.08 | 2.51 | 3.67 | 3.38 |
| — | -54.2% | -66.9% | -25.7% | -12.0% | +91.3% | +221.9% | +47.1% | +24.2% | -4.1% | +21.5% | +41.8% | -3.3% | |
| P/FCF | 3.60 | 2.89 | 8.26 | 7.39 | 5.38 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.78 | 3.91 | 5.00 | 9.22 | 4.42 | 8.76 | — | — | — | — | — | — | — |
| — | -55.4% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 4.16 | 4.92 | 5.15 | 8.93 | 4.35 | 8.50 | — | — | — | — | — | — | — |
| — | -42.1% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CorMedix Inc.'s operating margin was 46.0% in Q4 2025, down 3.3 pp QoQ and up 4.5 pp YoY. The trailing four-quarter average of 49.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 13.3% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 83.4% | 89.3% | 95.3% | 95.9% | 96.2% | 94.0% | 36.8% | — | — | — | — | — |
| — | -13.3% | -5.0% | +159.3% | — | — | — | — | — | — | — | — | — | |
| Operating Margin | 48.2% | 46.0% | 49.2% | 49.2% | 51.5% | 41.4% | -28.7% | -1898.1% | — | — | — | — | — |
| — | +10.9% | +271.6% | +102.6% | — | — | — | — | — | — | — | — | — | |
| Net Margin | 52.3% | 10.9% | 104.1% | 49.9% | 52.8% | 43.1% | -24.2% | -1755.5% | — | — | — | — | — |
| — | -74.7% | +529.5% | +102.8% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.6% | 3.6% | 36.5% | 11.8% | 20.7% | 18.8% | -5.3% | -27.2% | -22.6% | -19.2% | -14.7% | -21.9% | -19.4% |
| — | -80.8% | +789.5% | +143.5% | +191.7% | +197.6% | +64.1% | -24.1% | -16.4% | -30.5% | -26.9% | -75.1% | -69.0% | |
| ROA | 34.5% | 1.8% | 21.6% | 9.9% | 15.4% | 13.7% | -4.1% | -22.5% | -19.3% | -17.0% | -13.1% | -19.4% | -17.4% |
| — | -87.0% | +627.2% | +143.8% | +179.8% | +180.6% | +68.7% | -16.1% | -10.6% | -28.6% | -24.3% | -69.2% | -65.8% | |
| ROIC | 49.7% | 10.0% | 14.4% | 26.4% | 32.3% | 28.3% | -11.7% | -55.0% | -49.5% | -40.7% | -25.9% | -29.8% | -39.4% |
| — | -64.5% | +223.0% | +148.1% | +165.2% | +169.6% | +54.9% | -84.7% | -25.5% | +14.7% | +31.6% | +30.0% | +3.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
CorMedix Inc.'s Debt/EBITDA ratio is 2.1x, down from 2.7x last quarter — at a moderate level that warrants monitoring. The current ratio has weakened 40.6% YoY to 2.01x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.40 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| — | +5916.2% | +4100.1% | -84.7% | -61.9% | -35.8% | +12.2% | -14.3% | -23.8% | -34.7% | -43.0% | +7.3% | -4.4% | |
| Debt / EBITDA | 0.90 | 2.13 | 2.70 | 0.02 | 0.02 | 0.04 | — | — | — | — | — | — | — |
| — | +5278.0% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.01 | 2.01 | 1.94 | 7.82 | 4.21 | 3.39 | 3.96 | 4.79 | 6.65 | 6.97 | 11.61 | 7.39 | 12.15 |
| — | -40.6% | -50.9% | +63.4% | -36.7% | -51.4% | -65.9% | -35.3% | -45.2% | -26.1% | -1.5% | -40.4% | -16.5% | |
| Quick Ratio | 1.84 | 1.84 | 1.73 | 7.52 | 3.99 | 3.16 | 3.60 | 4.43 | 6.41 | 6.78 | 11.61 | 7.39 | 12.15 |
| — | -41.8% | -52.0% | +69.9% | -37.7% | -53.4% | -69.0% | -40.1% | -47.3% | -28.1% | -1.5% | -40.4% | -16.5% | |
| Interest Coverage | 53.97 | 30.60 | 56.45 | 3051.44 | 2063.95 | 1346.50 | -276.49 | -2157.56 | -1611.70 | -2249.46 | -742.11 | -1925.78 | -1203.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying CRMD stock.
CorMedix Inc.'s current P/E is 3.9x. The average P/E over the last 4 quarters is 9.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CorMedix Inc.'s current operating margin is 48.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CorMedix Inc.'s business trajectory between earnings reports.